Back to Agenda
Communicating Clinical Trial Results: Targeting the Patient Audience
Session Chair(s)
David B. Clemow, PHD
Advisor, Scientific Communications Information Strategy, Eli Lilly and Company, United States
This session will describe current venues where drug development organizations communicate clinical trial results to patients, how to best communicate, and the importance of meeting patients' needs for them and the drug development organization.
This session has been developed by the DIA Medical Writing, Patient Engagement, Medical Communications, and Clinical Trial Disclosure Communities.
Learning Objective : Describe current venues/channels where drug development organizations communicate clinical trial results to the patient; Illustrate how to best compose medical communications to meet patient needs; Discuss appropriate writing levels, important content components, and key considerations; Summarize the importance of meeting patient audience needs for them and the drug development organization.
Speaker(s)
David P. Leventhal, MBA
Enterprise Clinical Trial Data Sharing Lead, Global Data Dissemination, Pfizer Inc, United States
Communicating Medical Information
Colleen Zak, BSN
Founder / President, ARPKD/CHF Alliance, United States
Patient Perspective on Communication
Barbara Godlew, RN
Associate Consultant, Scientific Communications, GSC-Bio-Medicines, Eli Lilly and Company, United States
Communicating Through Clinical Trial Disclosures
David B. Clemow, PHD
Advisor, Scientific Communications Information Strategy, Eli Lilly and Company, United States
Communicating Through Advertising/Promotion
Have an account?